<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890069</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2102</org_study_id>
    <nct_id>NCT02890069</nct_id>
  </id_info>
  <brief_title>A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat</brief_title>
  <official_title>Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents&#xD;
      with immunomodulatory activity to identify the doses and schedule for combination therapy and&#xD;
      to preliminarily assess the safety, tolerability, pharmacological and clinical activity of&#xD;
      these combinations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">February 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>5.5 years</time_frame>
    <description>During the first two cycles Cycle = 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions and reductions</measure>
    <time_frame>5.5 years</time_frame>
    <description>Through study completion, an average of 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>6 years</time_frame>
    <description>Through study completion, an average of 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes between baseline and post-baseline laboratory parameters and vital signs</measure>
    <time_frame>6 years</time_frame>
    <description>Through study completion, an average of 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>6 years</time_frame>
    <description>Through study completion, an average of 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of Tumor Infiltrating Lymphocytes (TILs) by Hematoxylin</measure>
    <time_frame>6 years</time_frame>
    <description>Baseline and approximately after 2 cycles of treatment and at disease progression (an average of 6 months) Cycle = 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in ECG parameters in patients recieving PDR001 in combination with Panobinostat</measure>
    <time_frame>6 years</time_frame>
    <description>Baseline and end of treatment, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>6 years</time_frame>
    <description>per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for PDR001</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-PDR001 antibodies</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
    <description>per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Free Survival (TFS)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-PDR001 antibodies</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of TILs and myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate)</measure>
    <time_frame>6 years</time_frame>
    <description>Baseline and approximately after 2 cycles of treatment and at disease progression (an average of 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of Tumor Infiltrating Lymphocytes (TILs) by eosin (H&amp;E) stain</measure>
    <time_frame>6 years</time_frame>
    <description>Baseline and approximately after 2 cycles of treatment and at disease progression (an average of 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1 and 2, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per irRC</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for LCL161</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for Everolimus</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for Panobinostat</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum Plasma concentrations of QBM076 (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum and minimum Plasma concentrations of HDM201 (Cmax and Cmin)</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for QBM076</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach max concentration (Tmax) for HDM201</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for QBM076, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve calculated to the last concentration point (AUClast) for HDM201, as applicable</measure>
    <time_frame>6 years</time_frame>
    <description>Cycle 1 through cycle 6 in treatment period 1, an average of 6 months</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">298</enrollment>
  <condition>Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>CRC - PDR001 + LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC - PDR001 + LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNBC - PDR001 + LCL161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC - PDR001+ Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC - PDR001+ Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNBC - PDR001+ Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNBC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC - PDR001 + QBM076</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNBC - PDR001 + QBM076</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC- PDR001 + QBM076</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrollment to this combination arm is closed to further enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC - PDR001 + HDM201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation completed, expansion arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCC - PDR001 + HDM201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation completed, expansion arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>anti-PD1 antibody</description>
    <arm_group_label>CRC - PDR001 + LCL161</arm_group_label>
    <arm_group_label>CRC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_label>CRC - PDR001+ Everolimus</arm_group_label>
    <arm_group_label>NSCLC - PDR001 + LCL161</arm_group_label>
    <arm_group_label>NSCLC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_label>NSCLC - PDR001+ Everolimus</arm_group_label>
    <arm_group_label>TNBC - PDR001 + LCL161</arm_group_label>
    <arm_group_label>TNBC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_label>TNBC - PDR001+ Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCL161</intervention_name>
    <arm_group_label>CRC - PDR001 + LCL161</arm_group_label>
    <arm_group_label>NSCLC - PDR001 + LCL161</arm_group_label>
    <arm_group_label>TNBC - PDR001 + LCL161</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>CRC - PDR001+ Everolimus</arm_group_label>
    <arm_group_label>NSCLC - PDR001+ Everolimus</arm_group_label>
    <arm_group_label>TNBC - PDR001+ Everolimus</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <arm_group_label>CRC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_label>NSCLC - PDR001 + Panobinostat</arm_group_label>
    <arm_group_label>TNBC - PDR001 + Panobinostat</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QBM076</intervention_name>
    <arm_group_label>CRC - PDR001 + QBM076</arm_group_label>
    <arm_group_label>NSCLC- PDR001 + QBM076</arm_group_label>
    <arm_group_label>TNBC - PDR001 + QBM076</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <arm_group_label>CRC - PDR001 + HDM201</arm_group_label>
    <arm_group_label>RCC - PDR001 + HDM201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent prior to any procedure&#xD;
&#xD;
          -  Patients with advanced/metastatic cancer, with measurable disease as determined by&#xD;
             RECIST version 1.1, who have progressed despite standard therapy or are intolerant to&#xD;
             SOC, or for whom no standard therapy exists. Patients must fit into one of the&#xD;
             following groups:&#xD;
&#xD;
             • CRC •NSCLC • TNBC• RCC&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Patient must have a site of disease for biopsy, and be a candidate for tumor biopsy&#xD;
             according to the institution's guidelines. Patient must be willing to undergo a new&#xD;
             tumor biopsy at screening, and again during therapy on this study.&#xD;
&#xD;
          -  Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed&#xD;
             to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases&#xD;
             that require local CNS-directed therapy within prior 2 weeks.&#xD;
&#xD;
          -  Patients with known hypersensitivity to any of the components of an investigational&#xD;
             treatment will be excluded from participation in the corresponding arm but are&#xD;
             eligible for participation in other study arm; Patients that have a history of&#xD;
             hypersensitivity to rapamycin derivatives will be excluded from participation in the&#xD;
             everolimus arm&#xD;
&#xD;
          -  History of or current drug-induced interstitial lung disease or pneumonitis grade ≥2&#xD;
&#xD;
          -  Out of range lab values as defined in protocol&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV), or active Hepatitis C (HCV) virus. Escalation:&#xD;
             active Hepatitis B (HBV); Expansion: Patients with Chronic HBV currently on medication&#xD;
             will not be excluded.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function&#xD;
&#xD;
          -  Malignant disease, other than that being treated in this study&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For&#xD;
             cytotoxic agents that have major delayed toxicity and washout period is 6 weeks; prior&#xD;
             immunotherapy - washout is 4 weeks&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic therapy.&#xD;
&#xD;
          -  Patients requiring chronic treatment with systemic steroid therapy, other than&#xD;
             replacement dose steroids or treatment with low, stable dose of steroid (&lt;10 mg/day&#xD;
             prednisone or equivalent) for stable CNS metastatic disease.&#xD;
&#xD;
          -  Patients receiving systemic treatment with any immunosuppressive medication.&#xD;
&#xD;
          -  Major surgery within 2 weeks of the first dose of study treatment&#xD;
&#xD;
          -  Radiotherapy within 2 weeks of the first dose of study drug&#xD;
&#xD;
          -  Participation in an interventional, investigational study within 2 weeks of the first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Presence of ≥ CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and&#xD;
             ototoxicity, which are excluded if ≥ CTCAE grade 3) due to prior therapy.&#xD;
&#xD;
          -  Use of hematopoietic colony stimulating growth factors &lt;/= 3 weeks prior to first dose&#xD;
&#xD;
        Additional exclusion criteria for PDR001/LCL161&#xD;
&#xD;
          -  Patients requiring medications metabolized through CYP3A4/5 and have a narrow&#xD;
             therapeutic index or medications that are CYP3A4 substrates that cause QT prolongation&#xD;
&#xD;
          -  Patients requiring treatment with strong CYP2C8 inhibitors&#xD;
&#xD;
        Additional exclusion criteria for PDR001/Everolimus&#xD;
&#xD;
          -  Patients requiring treatment with moderate CYP3A4 inhibitors&#xD;
&#xD;
          -  Patients requiring treatment with a strong CYP3A4 inhibitor or inducer&#xD;
&#xD;
        Additional exclusion criteria for PDR001/Panobinostat-&#xD;
&#xD;
          -  Patient who received DAC inhibitors&#xD;
&#xD;
          -  Patient needing valproic acid during the study or within 5 days prior to first dose&#xD;
&#xD;
          -  Patients requiring medications that are sensitive CYP2D6 substrates areCYP2D6&#xD;
             substrates with a narrow therapeutic index or are anti-arrhythmic drugs/drugs with&#xD;
             QT-prolongation risks&#xD;
&#xD;
          -  Patients requiring a strong inhibitor or inducer of CYP3A4&#xD;
&#xD;
          -  Clinically significant, uncontrolled heart disease and/or recent cardiac event within&#xD;
             6 months prior to study&#xD;
&#xD;
          -  Unresolved diarrhea ≥ CTCAE grade 2 or a medical condition associated with chronic&#xD;
             diarrhea&#xD;
&#xD;
          -  Taking medications with QT prolongation risk or interval or inducing Torsade de&#xD;
             pointes&#xD;
&#xD;
        Additional exclusion criteria for PDR001/QBM076-&#xD;
&#xD;
          -  Patients requiring medications that are strong inducers or strong inhibitors of CYP3A4&#xD;
&#xD;
          -  Patients requiring medications with narrow therapeutic index CYP3A4 substrates&#xD;
&#xD;
          -  Women using any form of hormonal contraception (oral, injected, implanted,&#xD;
             transdermal) will be excluded (unless they are willing to switch to another effective&#xD;
             form of contraception under their physician's guidance)&#xD;
&#xD;
        Additional exclusion criteria for PDR001/HDM201-&#xD;
&#xD;
          -  Prior treatment with compounds with the same mode of action as proposed for HDM201,&#xD;
             i.e. an inhibition of the interaction of TP53 with HDM2, e.g. RG7112 or CGM097&#xD;
&#xD;
          -  Patients who require the following treatments moderate to strong CYP3A4 inhibitors;&#xD;
             any substrates of CYP3A4/5 with a narrow therapeutic index&#xD;
&#xD;
          -  Moderate to strong CYP3A4 inducers&#xD;
&#xD;
          -  Patients having out of range values for:&#xD;
&#xD;
        Absolute neutrophil count (ANC) &lt;1500/µL; Platelets &lt; 100 000/µL&#xD;
&#xD;
        Other protocol-defined inclusion exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Santa Monica Hematology / Oncology SC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Regents of the University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School SC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health San Antonio Mays Cancer Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR001</keyword>
  <keyword>CRC</keyword>
  <keyword>TNBC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>RCC</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Bayesian logistic regression model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

